Discover how BioCryst Pharmaceuticals' patent for complement system inhibitors offers groundbreaking treatment options for various diseases.
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the ...
In a note to clients, the analysts at Mizuho cut the firm's price target for the stock to $52 from $60 per share, saying they have updated their model. APLS's stock is currently trading at $43.87, ...